Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Healthcare Biotechnology
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Instil Bio Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by awol1on Apr 29, 2008 9:14pm
426 Views
Post# 15021368

explanation on 308,000 share trade please

explanation on 308,000 share trade please
15:41:01  T  0.35  -0.01  250  84  Ind Trading  80  National Bank  E 
15:38:27  T  0.36  -0.01  500  1  Anonymous  80  National Bank  K 
13:58:24  T  0.36  -0.01  2,500  80  National Bank  19  Desjardins  K 
13:28:00  T  0.34  -0.02  297  84  Ind Trading  2  RBC  E 
12:47:58  T  0.35  -0.02  308,000  2  RBC  2  RBC  K 
12:47:53  T  0.35  -0.02  85  80  National Bank  84  Ind Trading  E 
12:47:53  T  0.35  -0.02  5,500  80  National Bank  2  RBC  K 
12:47:53  T  0.35  -0.02  5,000  79  CIBC  2  RBC  K 
12:47:53  T  0.35  -0.02  10,000  80  National Bank  2  RBC  K 
12:47:53  T  0.365  -0.005  5,000  80  National Bank  2  RBC  K 

 Could someone explain the 308,000 share trade from 2 RBC to 2 RBC at 12:47 to me.  The transfer happened today, April 29th.  To me it looks like its to and from the same company and/or person or company but i'm not sure about it.

 Kinda hoping that something interesting could/should happen with this stock.  They should be releasing the final results of Phase III tests on the drug the put the release out in January.  Would this have something positive to do with that?
 Thanks in advance!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested